Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data

INTRODUCTION/OBJECTIVES: To evaluate the incidence rate (IR) of tuberculosis (TB) and viral hepatitis B and C (HBV/HCV) during certolizumab pegol (CZP) treatment, worldwide and in Asia-Pacific countries, across clinical trials and post-marketing reports (non-interventional studies and real-world pra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Chak Sing, Chen, Yi-Hsing, Lim, Keith, de Longueville, Marc, Arendt, Catherine, Winthrop, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895783/
https://www.ncbi.nlm.nih.gov/pubmed/32740672
http://dx.doi.org/10.1007/s10067-020-05248-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895783/
https://www.ncbi.nlm.nih.gov/pubmed/32740672
http://dx.doi.org/10.1007/s10067-020-05248-4

Ejemplares similares